Español
Nederlands
Italiano
Deutsch
Français
Português
This January 8, 2025, shareholders of Merck Sharp & Dohme will receive 0,81 dollars per share in dividends.
Investors wishing for dividends from Merck Sharp & Dohme (MRK), consider: December 13, 2024 is crucial to buy, and the Record Date, December 16, 2024, is when eligibility is established.
Merck Sharp & Dohme (MRK) paid a dividend of 0.77 dollars on October 7, 2024.
Merck Sharp & Dohme, listed on the New York Stock Exchange under the ticker symbol MRK, has paid a steady, stable dividend, with a brief dip in dividend progress beginning in 1999, but has remained moderately increasing since then.
The Company's Shareholders' Meeting is in charge of evaluating and deciding the value of the amount to be deposited, which has been leveled year after year, being deposited between the 8th and 10th of the months of January, April, July and October of each year.
The dividend yield recorded is close to 2.60% with a price-earnings ratio of 21.30.
Join +33,000 investors who get notifications, analysis and news.
Payout Ratio Merck Sharp & Dohme Dividends
Dividend calendar of Merck Sharp & Dohme
These are the most important events of the Merck Sharp & Dohme calendar in 2025:
| Event | Day |
|---|---|
| Last trading date | December 13, 2024 |
| Ex-Dividend (Ex-Date) | December 16, 2024 |
| Record date | December 16, 2024 |
| Date of payment | January 8, 2025 |
Information about Merck Sharp & Dohme
Merck Sharp & Dohme, or MSD, is a research and development-oriented pharmaceutical company.
Its origins date back to 1668 in Germany as a pharmacy acquired by Friedrich Jacob Merk, which remained a family business for decades until 1816 when Emanuel Merk and his sons converted it into a pharmaceutical and chemical factory.
Several decades later, the Merck family created Merck & Co. in New York, USA, as the company's first foreign subsidiary, although it suffered some problems during World War I, it managed to establish itself as an independent organization, merging in 2009 with Schering-Plough.
Currently headquartered in Kenilworth (New Jersey), with more than thirty factories distributed in various parts of the world and covering a market of 120 countries, it has more than 56 thousand employees, making it one of the most important companies in its area, even larger than its German parent company.
It is extensively engaged in research, developing, compounding and commercializing a diversity of drugs for both human and animal treatments, specializing in oncology, vaccine development, infectious diseases, cardiometabolic disorders and antivirals for COVID 19.
Frequently asked questions about Merck Sharp & Dohme dividends
Merck Sharp & Dohme is listed on the New York Stock Exchange and is part of the Nyse.
Merck Sharp & Dohme has the Ticker or stock code MRK.
The CEO of Merck Sharp & Dohme in 2025 is Mr. Robert M. Davis J.D..